News|Videos|April 9, 2026

The Weekly Dose: Orforglipron Data, Sports Medicine, and Nusinersen Approval

Fact checked by: Ron Panarotti

This week's episode highlights new data on the newly approved oral GLP-1, orforglipron, the growing role of sports pharmacists, and FDA approval of a higher-dose regimen for spinal muscular atrophy.

In this episode of The Weekly Dose, hosts Danielle Valletti, assistant editor, and Kennedy Ferruggia, associate editor at Pharmacy Times, break down 4 major stories shaping pharmacy practice.

New data, derived from the ORION analysis, suggests oral semaglutide (Wegovy; Novo Nordisk) may provide greater weight loss compared with orforglipron (Foundayo; Eli Lilly and Company)

In the Expert Spotlight, Brandon Welch, PharmD, highlights the growing role of clinical sports pharmacists ahead of the Sports Pharmacy Summit.

The FDA has approved orforglipron, the first oral glucagon-like peptide-1 receptor agonist without time, food, or water restrictions.

The FDA has also approved a higher-dose regimen of nusinersen (Spinraza; Biogen) for the treatment of spinal muscular atrophy.


Latest CME